Ani Pharmaceuticals (ANIP) Interest Expenses (2010 - 2013)

Ani Pharmaceuticals has disclosed Interest Expenses across 4 years of filings, most recently posting $98.0 for Q4 2013.

• Interest Expenses for Q4 2013 came in at $98.0, down 99.89% year-over-year; the trailing twelve-month figure through Sep 2014 was $98.0 (down 99.98% YoY), and the FY2013 annual result was $467000.0, down 64.81% from the prior year.
• Interest Expenses came in at $98.0 for Q4 2013 at Ani Pharmaceuticals, down from $374476.0 in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $501002.0 in Q2 2012 to a low of $98.0 in Q4 2013.
• The 4-year median for Interest Expenses is $172000.0 (2010), against an average of $175679.7.
• Across the five-year window, Interest Expenses soared 191.28% in 2012 and slumped 99.89% in 2013, its largest moves.
• Ani Pharmaceuticals' Interest Expenses stood at $172000.0 in 2010, then dropped by 3.74% to $165573.0 in 2011, then plunged by 46.93% to $87863.0 in 2012, then plunged by 99.89% to $98.0 in 2013.
• The last three Interest Expenses figures came in at $98.0 (Q4 2013), $374476.0 (Q2 2013), and $93000.0 (Q1 2013), per Business Quant data.